Indi, my comment was on Sarilumab not Praluent (Alirocumab). I do believe Sanofi/Regeneron will want to differentiate the WI for Praluent from the WI for Repatha.
- Forums
- ASX - By Stock
- UNS
- Indeed.com
Indeed.com, page-87
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online